ClinicalTrials.gg
TerminatedNCT01111565Updated Dec 21, 2021Results posted

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

A Phase 3 interventional study of Escitalopram and Aripiprazole in Major Depressive Disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 53 sites in 11 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-12-21.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated early due to Sponsor decision, closure of this combination therapy program is unrelated to any safety issues, no signals of concern.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
137
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 100 studies testing escitalopram in Depressive Disorder, Major — 7 open to participants now, 8 under way, 1 of them phase 3. Escitalopram · Depressive Disorder, Major.

Enrollment
41st of 99
137 · median 80
Started
2010
with 8 others
Phase 3
18 of 100
1 open now
Registered
50th of 100
by date
Lead sponsor
5 of 100
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 100 studies testing escitalopram in Depressive Disorder, Major, this one is the 41st largest by enrollment of the 99 interventional ones that give a count, is one of 9 that started in 2010, is one of 18 in phase 3, and was the 50th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

7 of the 100 studies testing escitalopram in Depressive Disorder, Major are open now, in 10 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About escitalopram

Escitalopram: first FDA approval 2002 (LEXAPRO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies testing escitalopram in Depressive Disorder, Major, or all of them as a file.
02

Study summary

This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an incomplete response to a prospective trial of Escitalopram, and report a treatment history for the current MDD episode of an inadequate response to at least one and no more than three adequate trials of an approved antidepressant other than Escitalopram. An inadequate response is defined as less than a 50% reduction in depressive symptom severity as assessed by the participant's self-report on the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ) and evaluated by the investigator as part of the participant's medical and psychiatric history. An adequate trial is defined as an antidepressant treatment for at least 6 weeks duration (or at least 3 weeks for combination treatments) at an approved dose as specified in the ATRQ.

Read the detailed description

The study will be organized as follows:

  • Screening Phase
  • Single-blind Prospective Treatment Phase
  • Single-blind Continuation Phase (Responder)or Double-blind Randomization Phase (non-Responder)
  • 30 day Post Treatment Follow-up

Assigned Interventions:

  • Escitalopram monotherapy
  • Aripiprazole/Escitalopram combination therapy
  • Aripiprazole monotherapy
03

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • Major Depressive Disorder
  • MDD
  • Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a current diagnosis of a major depressive episode. The current depressive episode must be ≥8 weeks in duration
  • Participants willing to discontinue all prohibited psychotropic medication starting from the time of signing the and during the study period
  • Participants with a 17-item Hamilton Depression Rating Scale (HAM-D17) Total Score ≥18 at the Baseline for the Prospective Treatment Phase

Exclusion criteria

Exclusion Criteria:

  • Lack of prior treatment with an antidepressant during the current depressive episode
  • Participants who report treatment with adjunctive or monotherapy antipsychotic treatment during the current depressive episode.
  • Participants experiencing hallucinations, delusions or any psychotic symptomatology in the current depressive episode
  • Participants with epilepsy or significant history of seizure disorders
  • Participants with a current diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder
  • Participants who have received electroconvulsive therapy (ECT) in the last 10 years
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
137 participants (actual)

Study arms

  • Experimental
    Phase B: Single-blind Prospective Treatment Phase

    Escitalopram 10 mg capsule, orally, once daily increased to 20 mg/day at the Week 1 (end of Week 1) based upon tolerability profile, for 8 weeks. No dose reductions were allowed after Week 4 and no dose increments were allowed after Week 3. Participants with incomplete response at the end of the Phase B (Week 8) entered Phase C and the rest of the participants continued to Phase B+.

    Drug: Escitalopram

  • Experimental
    Phase B+: Single-blind Phase B Responders

    Participants with response (≥50% reduction in depressive symptom severity in HAM-D17 Total Score; or a HAM-D17 Total Score of \<14 at Week 8 or a Clinical Global Impression of Improvement (CGI-I) Score of \<3 at the Week 6 or 8) at the end of the Phase B (Week 8) continued treatment with the single-blind escitalopram monotherapy at the dose (10 or 20 mg/day) taken during the final week of Phase B, for an additional 6 weeks (Up to Week 14), in Phase B+.

    Drug: Escitalopram

  • Experimental
    Phase C: Aripiprazole/Escitalopram Combination

    Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily in combination with the escitalopram 10 or 20 mg orally for 6 weeks (Up to Week 14), in Phase C. No dose adjustments were allowed for escitalopram during Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated.

    Drug: Escitalopram · Drug: Aripiprazole

  • Experimental
    Phase C: Escitalopram Monotherapy

    Participants with incomplete response at Week 8 who were randomized to this arm group received escitalopram monotherapy 10 or 20 mg capsule, orally, once daily, whichever dose was taken during the final week of Phase B for 6 weeks (Up to Week 14), in Phase C. No dose adjustments were allowed for escitalopram monotherapy during Phase C.

    Drug: Escitalopram

  • Experimental
    Phase C: Aripiprazole Monotherapy

    Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily for 6 weeks (Up to Week 14), in Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated. No dose increments were allowed after Week 12; however, doses may have been decreased at any visit, based upon tolerability.

    Drug: Aripiprazole

Interventions

  • Escitalopram capsule administered orally, once daily without regard to meals.

  • Aripiprazole capsule administered orally, once daily without regard to meals.

06

What researchers measure

Primary outcomes

  1. Phase C: Mean Change From End of Phase B (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to End of Phase C (Week 14)

    The MADRS assessed severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms). Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. Last observation carried forward (LOCF) method was used for analyses.

    Time frame: Week 8 to Week 14

Secondary outcomes

  1. Phase C: Clinical Global Impression - Improvement Scale (CGI-I) Score at the End of Phase C

    CGI-I is a 7-point clinician-rated scale ranging from 1 to 7, rated as 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. A higher score indicates greater impairment. LOCF method was used for analyses.

    Time frame: Week 14

  2. Phase C: Mean Change From End of Phase B (Week 8) in the Sheehan Disability Scale (SDS) Mean Score to End of Phase C (Week 14)

    SDS is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. The participant is asked to rate the degree to which their functioning is impaired on an 11-point scale, ranging from 0 (not at all) to 10 (extremely). Scores of 0 to 3 indicate mild functional impairment, 4 to 6 indicate moderate functional impairment, and 7 to 9 indicate marked functional impairment. The scores for the 3 domains are summed into a total score that ranges from 0 (unimpaired) to 30 (highly impaired). A higher score indicates greater impairment. A negative change score indicates improvement. LOCF method was used for analyses.

    Time frame: Week 8 to Week 14

07

Results

Posted Dec 21, 2021
Limitations and caveats
The study was terminated early due to Sponsor decision, closure of this combination therapy program is unrelated to any safety issues, no signals of concern.

Participant flow

Participants took part in the study at 70 investigative sites in the United States, Canada, France, India, Malaysia, Poland, and South Africa from 4 October 2010 to 1 September 2011.

Phase B (Weeks 0 to 8)
Participant flow — Phase B (Weeks 0 to 8)
MilestonePhase B: Single-blind Prospective Treatment PhasePhase B+: Single-blind Phase B RespondersPhase C: Aripiprazole/Escitalopram CombinationPhase C: Escitalopram MonotherapyPhase C: Aripiprazole Monotherapy
Started1370000
Completed710000
Not completed660000
Withdrew: Lost to follow-up30000
Withdrew: Adverse event10000
Withdrew: Sponsor discontinued study580000
Withdrew: Investigator withdrew subject10000
Withdrew: Subject withdrew consent10000
Withdrew: Protocol deviation10000
Withdrew: Lack of efficacy as determined by the investigator10000
Phase B + and Phase C (Weeks 9 to 14)
Participant flow — Phase B + and Phase C (Weeks 9 to 14)
MilestonePhase B: Single-blind Prospective Treatment PhasePhase B+: Single-blind Phase B RespondersPhase C: Aripiprazole/Escitalopram CombinationPhase C: Escitalopram MonotherapyPhase C: Aripiprazole Monotherapy
Started026161415
Completed019111011
Not completed07544
Withdrew: Lost to follow-up00010
Withdrew: Adverse event00200
Withdrew: Sponsor discontinued study07323
Withdrew: Investigator withdrew subjects00010
Withdrew: Subjects withdrew consent00001

Outcome measures

PrimaryPhase C: Mean Change From End of Phase B (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to End of Phase C (Week 14)

The MADRS assessed severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms). Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. Last observation carried forward (LOCF) method was used for analyses.

Time frame:
Week 8 to Week 14
Reported as:
Least squares mean · score on a scale
Phase C: Mean Change From End of Phase B (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to End of Phase C (Week 14)
score on a scalePhase C: Aripiprazole/Escitalopram CombinationPhase C: Escitalopram MonotherapyPhase C: Aripiprazole Monotherapy
Phase C: Mean Change From End of Phase B (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to End of Phase C (Week 14)-9.0 ± 2.1-3.6 ± 2.2-3.8 ± 2.1
Statistical analysis
  • Phase C: Aripiprazole/Escitalopram Combination vs Phase C: Escitalopram Monotherapy · ANCOVA · p = =0.079 · Treatment difference: -5.4 · 95% CI -11.5 to 0.7
  • Phase C: Aripiprazole/Escitalopram Combination vs Phase C: Aripiprazole Monotherapy · ANCOVA · p = =0.085 · Treatment difference: -5.2 · 95% CI -11.2 to 0.7
SecondaryPhase C: Clinical Global Impression - Improvement Scale (CGI-I) Score at the End of Phase C

CGI-I is a 7-point clinician-rated scale ranging from 1 to 7, rated as 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. A higher score indicates greater impairment. LOCF method was used for analyses.

Time frame:
Week 14
Reported as:
Mean · score on a scale
Phase C: Clinical Global Impression - Improvement Scale (CGI-I) Score at the End of Phase C
score on a scalePhase C: Aripiprazole/Escitalopram CombinationPhase C: Escitalopram MonotherapyPhase C: Aripiprazole Monotherapy
Phase C: Clinical Global Impression - Improvement Scale (CGI-I) Score at the End of Phase C2.5 ± 0.23.0 ± 0.22.9 ± 0.2
Statistical analysis
  • Phase C: Aripiprazole/Escitalopram Combination vs Phase C: Escitalopram Monotherapy · Cochran-Mantel-Haenszel · p = =0.148 · Treatment difference: -0.5 · 95% CI -1.1 to 0.1Cochran-Mantel-Haenszel Row Mean Scores Test was used to determine the p-value.
  • Phase C: Aripiprazole/Escitalopram Combination vs Phase C: Aripiprazole Monotherapy · Cochran-Mantel-Haenszel · p = =0.242 · Treatment difference: -0.4 · 95% CI -1.0 to 0.3Cochran-Mantel-Haenszel Row Mean Scores Test was used to determine the p-value.
SecondaryPhase C: Mean Change From End of Phase B (Week 8) in the Sheehan Disability Scale (SDS) Mean Score to End of Phase C (Week 14)

SDS is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. The participant is asked to rate the degree to which their functioning is impaired on an 11-point scale, ranging from 0 (not at all) to 10 (extremely). Scores of 0 to 3 indicate mild functional impairment, 4 to 6 indicate moderate functional impairment, and 7 to 9 indicate marked functional impairment. The scores for the 3 domains are summed into a total score that ranges from 0 (unimpaired) to 30 (highly impaired). A higher score indicates greater impairment. A negative change score indicates improvement. LOCF method was used for analyses.

Time frame:
Week 8 to Week 14
Reported as:
Least squares mean · score on a scale
Phase C: Mean Change From End of Phase B (Week 8) in the Sheehan Disability Scale (SDS) Mean Score to End of Phase C (Week 14)
score on a scalePhase C: Aripiprazole/Escitalopram CombinationPhase C: Escitalopram MonotherapyPhase C: Aripiprazole Monotherapy
Phase C: Mean Change From End of Phase B (Week 8) in the Sheehan Disability Scale (SDS) Mean Score to End of Phase C (Week 14)-1.6 ± 0.7-1.8 ± 0.7-0.6 ± 0.7
Statistical analysis
  • Phase C: Aripiprazole/Escitalopram Combination vs Phase C: Escitalopram Monotherapy · ANCOVA · p = =0.910 · Treatment difference: 0.1 · 95% CI -1.8 to 2.1
  • Phase C: Aripiprazole/Escitalopram Combination vs Phase C: Aripiprazole Monotherapy · ANCOVA · p = =0.291 · Treatment difference: -1.0 · 95% CI -3.0 to 0.9

Adverse events

Collected over From first dose of study drug through 30 days after the last dose of study drug (up to approximately 22 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase B: Single-blind Prospective Treatment Phase0/137 (0%)0/137 (0%)65/137 (47.4%)
Phase B+: Single-blind Phase B Responders0/26 (0%)0/26 (0%)4/26 (15.4%)
Phase C: Aripiprazole/Escitalopram Combination0/16 (0%)0/16 (0%)12/16 (75%)
Phase C: Escitalopram Monotherapy0/14 (0%)0/14 (0%)11/14 (78.6%)
Phase C: Aripiprazole Monotherapy0/15 (0%)0/15 (0%)13/15 (86.7%)
Most frequent other events
Showing 10 of 51
Most frequent other events
EventPhase B: Single-blind Prospective Treatment PhasePhase B+: Single-blind Phase B RespondersPhase C: Aripiprazole/Escitalopram CombinationPhase C: Escitalopram MonotherapyPhase C: Aripiprazole Monotherapy
RestlessnessPsychiatric disorders2/1370/262/160/144/15
Dry mouthGastrointestinal disorders7/1371/261/161/143/15
SomnolenceNervous system disorders8/1371/261/161/143/15
Upper respiratory tract infectionInfections and infestations3/1370/263/160/140/15
FatigueGeneral disorders7/1370/261/162/141/15
NauseaGastrointestinal disorders18/1372/262/160/142/15
HeadacheNervous system disorders15/1370/261/161/142/15
InsomniaPsychiatric disorders2/1370/261/161/142/15
AstheniaGeneral disorders1/1370/262/160/141/15
AkathisiaNervous system disorders1/1370/262/161/141/15

Baseline characteristics

Phase B Sample included all participants who took at least one dose of escitalopram as indicated on the dosing record.

Age, Continuous
Age, Continuous(Years)Phase B: Single-blind Prospective Treatment Phase
Mean43.3 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Phase B: Single-blind Prospective Treatment Phase
Female90
Male47
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase B: Single-blind Prospective Treatment Phase
Hispanic or Latino6
Not Hispanic or Latino129
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase B: Single-blind Prospective Treatment Phase
American Indian or Alaska Native0
Asian10
Native Hawaiian or Other Pacific Islander0
Black or African American26
White90
More than one race0
Unknown or Not Reported11
08

Study locations

53 sites
  • Tucson, Arizona 85710, United States
  • Chino, California 91710, United States
  • Riverside, California 92506, United States
  • Torrance, California 90502, United States
  • Hamden, Connecticut 06518, United States
  • Marietta, Georgia 30060, United States
  • Belmont, Massachusetts 02478, United States
  • Weymouth, Massachusetts 02190, United States
  • Saint Charles, Missouri 63301, United States
  • Saint Louis, Missouri 63141, United States
  • Brooklyn, New York 11235, United States
  • Garfield Heights, Ohio 44125, United States
  • Philadelphia, Pennsylvania 19107, United States
  • East Providence, Rhode Island 02914, United States
  • Kirkland, Washington 98033, United States
  • Penticton, British Columbia V2A 4M4, Canada
  • Vancouver, British Columbia V6Z 2L4, Canada
  • Burlington, Ontario L7R 4E2, Canada
  • Osijek, 31000, Croatia
  • Rijeka, 51000, Croatia
  • Zagreb, 10000, Croatia
  • Zagreb, 10090, Croatia
  • Douai, 59500, France
  • Elancourt, 78990, France
  • Baja, 6500, Hungary
  • Balassagyarmat, 2660, Hungary
  • Budapest, 1053, Hungary
  • Budapest, 1137, Hungary
  • Gyula, 5700, Hungary
  • Hyderabad, Andhra Pradesh 500034, India
  • Visakhapatnam, Andhra Pradesh 530002, India
  • Mumbai, Maharashtra 400605, India
  • Tampoi, Johor Bahru 80100, Malaysia
  • Tampoi, Johor Bahru 81200, Malaysia
  • Kajang, Selangor 43000, Malaysia
  • Kuala Lumpur, 50603, Malaysia
  • Belchatow, 97-400, Poland
  • Bialystok, 15-464, Poland
  • Bialystok, 15-879, Poland
  • Study Site 1
    Choroszcz, 16-070, Poland
  • Study Site 2
    Choroszcz, 16-070, Poland
  • Sosnowiec, 41-200, Poland
  • Tuszyn, 95-080, Poland
  • Study Site 1
    Cape Town, 7530, South Africa
  • Study Site 2
    Cape Town, 7530, South Africa
  • Durban, 3630, South Africa
  • Pretoria, 0001, South Africa
  • Pretoria, 0145, South Africa
  • Pretoria, 0181, South Africa
  • Barcelona, 08003, Spain
  • Salamanca, 37002, Spain
  • Göteborg, 41685, Sweden
  • Malmö, 21135, Sweden
09

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2010 to primary completion in Sep 2011, 10 months.

Results were first posted in Dec 2021, 10 years 3 months after primary completion. A results delay was requested in Aug 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2010
First posted
Apr 27, 2010
StartActual
Oct 4, 2010
Primary completionActual
Sep 1, 2011
CompletionActual
Sep 1, 2011
Results delay requested
Aug 17, 2012
Results first posted
Dec 21, 2021
Last update
Dec 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01111565
Responsible party
Sponsor
First posted
Apr 27, 2010
Start date
Oct 4, 2010
Primary completion
Sep 1, 2011
Completion
Sep 1, 2011
Results posted
Dec 21, 2021
Last update
Dec 21, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Escitalopram · Aripiprazole

Start the discussion